Literature DB >> 10559061

Gene therapy: lessons learnt from the past decade. Interview by Clare Thompson.

R A Morgan, R M Blaese.   

Abstract

Mesh：

Year:  1999        PMID： 10559061      PMCID： PMC1129086          DOI： 10.1136/bmj.319.7220.1310

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  14 in total

Review 1.  Therapeutic angiogenesis.

Authors:  T D Henry
Journal:  BMJ       Date:  1999-06-05

Review 2.  Use of adeno-associated virus as a general transduction vector for mammalian cells.

Authors:  N Muzyczka
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

3.  Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

Authors:  G Schiedner; N Morral; R J Parks; Y Wu; S C Koopmans; C Langston; F L Graham; A L Beaudet; S Kochanek
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

Review 4.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

5.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

6.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

Authors:  S A Rosenberg; P Aebersold; K Cornetta; A Kasid; R A Morgan; R Moen; E M Karson; M T Lotze; J C Yang; S L Topalian
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

7.  In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides.

Authors:  B T Kren; P Bandyopadhyay; C J Steer
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

8.  T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors:  R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

9.  T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients.

Authors:  S R Riddell; M Elliott; D A Lewinsohn; M J Gilbert; L Wilson; S A Manley; S D Lupton; R W Overell; T C Reynolds; L Corey; P D Greenberg
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

10.  Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.

Authors:  C E Dunbar; M Cottler-Fox; J A O'Shaughnessy; S Doren; C Carter; R Berenson; S Brown; R C Moen; J Greenblatt; F M Stewart
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113
View more
  1 in total

Review 1.  Applications of genetic engineering in veterinary medicine.

Authors:  K Ciftci; P Trovitch
Journal:  Adv Drug Deliv Rev       Date:  2000-09-15       Impact factor: 15.470
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.